TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Read more about TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.
Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Read more about Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts.
Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific. Read more about Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific.
Quality of life in adults with brain tumors: current knowledge and future directions. Read more about Quality of life in adults with brain tumors: current knowledge and future directions.
In reference to lamborn et Al. (Neuro-oncology. 2008;10:162-170). Read more about In reference to lamborn et Al. (Neuro-oncology. 2008;10:162-170).
Quality of life in low-grade glioma patients receiving temozolomide. Read more about Quality of life in low-grade glioma patients receiving temozolomide.
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Read more about Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium.
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. Read more about A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Read more about Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Read more about Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
